Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP.
about
Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesisComparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue diseaseQuantification of HTLV-I proviral load in experimentally infected rabbitsHTLV-1, Immune Response and AutoimmunityTreatment of HTLV-I-Associated Myelopathy / Tropical Spastic Paraparesis: Towards Rational Targeted TherapyHigh expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic diseaseAbnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccineHTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1)Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease.Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutationsHTLV-1 induces a Th1-like state in CD4+CCR4+ T cells.Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathyCo-dependence of HTLV-1 p12 and p8 functions in virus persistenceAn antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.Identification of TL-Om1, an adult T-cell leukemia (ATL) cell line, as reference material for quantitative PCR for human T-lymphotropic virus 1.Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease.Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriersMinocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease.Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from JamaicaInhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1.Tumor immunity against adult T-cell leukemia.HAM/TSP-derived HTLV-1-infected T cell lines promote morphological and functional changes in human astrocytes cell lines: possible role in the enhanced T cells recruitment into Central Nervous SystemStandardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study.Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies iHumoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individualsRetrovirally induced CTL degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-I-associated neurologic diseaseMemory lineage relationships in HTLV-1-specific CD8+ cytotoxic T cells.Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders.Neuroimmunity of HTLV-I Infection.Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.Inflammatory manifestations of HTLV-1 and their therapeutic options.Multistability in a model for CTL response to HTLV-I infection and its implications to HAM/TSP development and prevention.Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy.High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease.Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.Modulation of T cell responses in HTLV-1 carriers and in patients with myelopathy associated with HTLV-1.Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.
P2860
Q21131133-AF4D6141-8AD9-4F7C-B937-B65EF9190A2BQ24653987-511A550F-EF77-4AF9-B252-F280A708861EQ24805302-B20B3CAF-1DD9-4F5A-8103-4D464EA55B86Q24811582-9454CC68-5763-4347-8B71-C4EA716F13ECQ26771801-D8E8148F-F12E-4A0F-8FBC-9407B6722303Q28972318-CAB5D3F5-2589-4D2F-A20C-7FCA16C62273Q30973354-5704FDDA-6B06-4E99-8288-D1C63F11CCFCQ33490596-C74F1E52-B26D-4558-9708-901537554C39Q33651831-66423AF5-5A0A-47FF-8312-90E9FEEE7F66Q33709237-B3E0E8F7-97F8-477F-B4DE-69B435F80FC0Q33747593-113A6F32-A0F8-4D4C-BB58-577B2C2E2969Q33768325-0551F1B9-EDE7-485E-A363-4E554A901DB5Q33858337-EBFD8001-153D-4F65-AC9E-686ECF39D798Q33944201-F198EF31-CC3F-4BC7-AB19-3B56725C5727Q34359754-183F3C2D-220E-42C3-9863-D6D0B4570052Q34466396-AF1F4896-757A-4261-B2C9-932CDA9030FBQ34756124-CD2E5C6A-A013-4E54-A527-FD2EC276C829Q34983086-17B3E334-C80F-40DA-BE69-10EE0FC4CA9BQ35276727-C4106051-A539-4A64-BD73-FC3198F1C8ECQ35537421-C4D3E3AD-0A8A-48DD-B2C1-5DE4D02A1525Q35812057-8D8C6A1B-24F4-4BA0-B034-1DD8124BCE03Q35891629-8B87C93E-A090-4FEC-8B2F-3B55ACA89AB2Q35947986-4CDE4199-6BA3-4AE6-8B2F-8F0B75491554Q36132707-CF880F6A-7A23-4B1A-A0BE-F4999549DF29Q36156395-DE67EEF8-A728-43B4-9B49-99F508D7BA42Q36174049-49ACA90A-8006-4520-AFF1-23DE7AAAFAB0Q36399192-5C9DEB94-ED37-4B23-B684-50AA247DFBE3Q36646919-2C429045-3C97-49CA-B1D2-B3E526B75328Q36868753-67D63FE2-5B88-4211-A3E4-45383A42E321Q37183161-283B4EED-63C6-4DBF-B6FB-24A735BE7FD7Q37381691-2932957D-58E4-4F72-862C-EE0CC74339A9Q37741036-8AE826BB-2E90-4833-8A40-24C2F2F9DF5CQ38128799-1D0B11EB-59AD-43DD-8555-5779B15C3A9CQ38262169-809EFF4C-F022-4717-AF9B-F2974C63FF55Q38546539-67B4B780-695A-46A0-BE05-C9CDC51CCD20Q38874995-7861D554-03BB-4C88-BF24-6A18E3D84F7CQ39028778-E22487D2-2428-41B2-A7BE-A196C745FD57Q39294381-66F450A1-0DAF-411D-A33F-7A508DEAC586Q39430207-8BD2C9E8-FC2D-45FB-8A4F-6E1CF15B1D3AQ40008331-ADE1997B-9B61-4BCE-813E-A9D51714F51D
P2860
Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@en
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@nl
type
label
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@en
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@nl
prefLabel
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@en
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@nl
P2093
P2860
P921
P356
P1433
P1476
Increased HTLV-I proviral load ...... id from patients with HAM/TSP.
@en
P2093
P2860
P304
P356
10.1002/ANA.10065
P577
2001-12-01T00:00:00Z